

Bijlage. Overzicht lopende klinische trials in SjD:

Phase I	Phase II			Phase III
BMS-986325 BMS	Iscalimab Novartis	S95011 Servier	Anifrolumab AstraZeneca	Ianalumab Novartis
CD19/BCMA CAR T-cells	Baricitinib Eli Lilly	Tofacitinib NIDCR	Branebrutinib BMS	Dazodalibep Amgen
	Nipocalimab Janssen	Efgartigimod Argenx	Telitacicept RemeGen	Deucravacitinib BMS
	SAR441344 Sanofi	AMG329 Amgen		

Mechanisms of action

Anti-CD40 mAb	Anti-CD40 mAb	Anti-IL7R mAb	Anti-IFNAR mAb	Anti-BAFF-R mAb
B cell depletion	JAK1/2 inhibitor	JAK inhibitor	BTK inhibitor	CD40L blockade
	Anti-FcRn mAb	Anti-FcRn mAb	TACI-Ig	TYK2 inhibitor
	CD40L blockade	Anti-FLT3-L mAb		

Updated in April 2024 from: Arends S, Verstappen GM, de Wolff L, Pringle S, Kroese FGM, Vissink A, Bootsma H. Why do drug treatments fail in Sjögren's disease? Considerations for treatment, trial design and interpretation of clinical efficacy. Expert Rev Clin Immunol. 2023 Jul-Dec;19(10):1187-1194. doi: 10.1080/1744666X.2023.2234641. Epub 2023 Aug 8. PMID: 37551702.